The selection from international journals 4/2025
CommentGastroent Hepatol 2025; 79(4): 305–307.
pdfOn the question of the interchangeability of monoclonal biosimilar antibodies in the treatment of immune-mediated inflammatory diseases
CommentGastroent Hepatol 2023; 77(1): 34–37. doi: 10.48095/ccgh202334
Literaturepdf Milan Lukáš, Ladislav Šenolt, Spyridon GkalpakiotisThe benefit of biosimilar monoclonal antibodies in the therapy of inflammatory bowel diseases
CommentGastroent Hepatol 2022; 76(5): 447–452. doi: 10.48095/ccgh2022447
SummaryLiteraturepdf Milan LukášKomentář k doporučení Americké gastroenterologické asociace (AGA) pro léčbu středně těžké a těžké Crohnovy nemoci
CommentGastroent Hepatol 2021; 75(5): 451–453. doi: 10.48095/ccgh2021451
Literaturepdf Milan LukášKomentář ke článku „The influence of microscopic inflammation at resection margins on early postoperative endoscopic recurrence after ileocaecal resection for Crohn’s disease“ (Journal Crohn’s Colitis 2020; 14 (3): 361–368
CommentGastroent Hepatol 2021; 75(1): 38–39. doi: 10.48095/ccgh202138
Literaturepdf Milan LukášComment on drug profile Rifaximin – therapeutic properties
CommentGastroent Hepatol 2017; 71(4): 355.
Literaturepdf Přemysl FričComment on article Biosimilar infliximab in anti-TNF naïve IBD patients – 1-year clinical follow-up
CommentGastroent Hepatol 2017; 71(4): 323–324. doi:10.14735/amgh2017323
Literaturepdf Peter D. R. HigginsUstekinumab – a new biologic drug for the treatment of Crohn’s disease
CommentGastroent Hepatol 2017; 71(1): 36–39. doi:10.14735/amgh201736
Literaturepdf Milan Lukáš